NCT04304352招募中2 期
A Phase II Study of Metronomic Oral Chemotherapy With Cyclophosphamide Plus Capecitabine and Vinorelbine in Metastatic Breast Cancer Patients
European Institute of Oncology1 个研究点 分布在 1 个国家目标入组 162 人开始时间: 2011年7月29日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 162
- 试验地点
- 1
- 主要终点
- Time to progression (TTP)
研究概览
简要总结
This is a phase II study assessing the activity and safety of metronomic chemotherapy with cyclophosphamide and capecitabine and vinorelbine in advanced breast cancer patient in four different cohort of patients:
- Untreated (naïve) patients with endocrine responsive disease
- Pretreated patients with endocrine responsive disease
- Untreated (naïve) patients with triple negative disease
- Pretreated patients with triple negative disease The primary endpoint will be the progression-free survival
详细描述
This is an institutional, monocentric, open-label, phase II study of oral "metronomic" Vinorelbine plus Capecitabine and Cyclophosphamide (VEX) in patients with advanced breast cancer .
Patients will receive the combination regimen as follow:
Cyclophosphamide 50 mg daily Capecitabine 500 mg, thrice daily Vinorelbine 40 mg orally thrice a week
Four independent cohorts of patients will be evaluated in the study:
- Untreated (naïve) patients with endocrine responsive disease
- Pretreated patients with endocrine responsive disease
- Untreated (naïve) patients with triple negative disease
- Pretreated patients with triple negative disease Combination will be administered until disease progression or unacceptable toxicity.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 99 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Pre- or post-menopausal women (age ≥18 years) with histologically or cytologically (cell block) proven, locally advanced (inoperable) or metastatic breast carcinoma. Immunohistochemical evaluation of estrogen receptor (ER), progesterone receptor (PgR), human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor (EGFR) according to European Institute of Oncology guidelines is mandatory.
- •Patients with HER2 overexpressed tumors, are eligible if they had received previous trastuzumab therapy for advanced disease, and/or a treatment with anti HER2 targeted therapy.
- •Patients fulfilling one of the following criteria:
- •Patients with measurable disease as per RECIST 1.1 criteria. This is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as 20 mm with conventional techniques or as 10 mm with spiral CT scan
- •Patients with bone lesions, lytic or mixed (lytic + sclerotic), in the absence of measurable disease as defined by RECIST 1.1 criteria. Bone lesions must be evaluable by plain CT or MRI. Patients with lesions identified only on radionucleotide bone scan are not eligible.
- •Patients may have received any primary and/or adjuvant therapies, as any previous lines of chemotherapy and endocrine therapy for advanced disease. Patients may have received metronomic capecitabine, methotrexate and cyclophosphamide in adjuvant setting at least 12 months before study entry
- •Previous treatment with capecitabine, cyclophosphamide and vinorelbine not in metronomic schedule for advanced disease is allowed, provided that the patient has progressive disease at study entry and the patients should not be defined as "refractory" to treatments (Pathological Response or Complete Response or Stable Disease > 6 months).
- •Patients may have had previous hormonal therapy as treatment of metastatic disease provided that the patient has progressive disease at study entry. Hormonal therapy must be discontinued prior to study entry, excluding Luteinizing Hormone-Releasing Hormone (LHRH) analogue.
- •Life expectancy greater than 6 months.
- •Eastern Cooperative Oncology Group (ECOG) Performance Status performance status <2
- •Patients must have normal organ and marrow function as defined below:
- •leukocytes ≥ 3,000/μL
- •absolute neutrophil count ≥ 1,000/μL
- •platelets ≥ 100,000/μL
- •Haemoglobin ≥ 10 g/dl
- •total bilirubin within normal institutional limits
- •Aspartate Aminotransferase (AST)/Alanine Aminotransferase (ALT) ≤ 2 X institutional upper limit of normal
- •creatinine within normal institutional limits OR
- •creatinine clearance ≥ 60 mL/min/1.73 m for patients with creatinine levels above institutional normal
- •Geographically accessible for follow up.
- •Ability to understand and the willingness to sign a written informed consent document.
排除标准
- •Previous metronomic chemotherapy for advanced disease with capecitabine, cyclophosphamide and vinorelbine
- •Patients defined as "refractory" to capecitabine, cyclophosphamide and vinorelbine (Progression Disease or Stable Disease < 6 months).
- •Presence of symptomatic cerebral or leptomeningeal involvement.
- •Previous or concomitant other malignancy except basal or squamous cell carcinoma of the skin or adequately treated in situ carcinoma of the cervix.
- •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- •Malabsorption syndrome or disease affecting significantly gastrointestinal function or major resection of the stomach or proximal small bowel that could affect absorption of oral vinorelbine
- •Concurrent treatment with any other anti-cancer therapy except LHRH analogue.
- •Patients with pre-existing motor or sensory peripheral neuropathy grade 2 according to NCI criteria
研究组 & 干预措施
Metronomic VEX
Experimental
Metronomic VEX (Oral Cyclophosphamide 50 mg daily continuous, Oral Capecitabine 500 mg, thrice daily continuous, Oral Vinorelbine 40 mg day 1,3 and 5 every week
干预措施: Vinorelbine (Drug)
Metronomic VEX
Experimental
Metronomic VEX (Oral Cyclophosphamide 50 mg daily continuous, Oral Capecitabine 500 mg, thrice daily continuous, Oral Vinorelbine 40 mg day 1,3 and 5 every week
干预措施: Capecitabine (Drug)
Metronomic VEX
Experimental
Metronomic VEX (Oral Cyclophosphamide 50 mg daily continuous, Oral Capecitabine 500 mg, thrice daily continuous, Oral Vinorelbine 40 mg day 1,3 and 5 every week
干预措施: Cyclophosphamide (Drug)
结局指标
主要结局
Time to progression (TTP)
时间窗: 28 days
the time between the first study dose administration and the date of progression of the disease or cancer-related death, whichever occurs first
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Clinical Study of Metronomic Oral Cyclophosphamide in Patients With Advanced SarcomasSarcomaNCT01716689National Cancer Centre, Singapore24
进行中（未招募）
不适用
A phase II study evaluating the role of the combination of Vinorelbine,cyclophosphamide and capecitabine administered metronomically, that means low doses daily orally, in patients with advanced breast cancerMedDRA version: 14.1Level: PTClassification code 10055113Term: Breast cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Metastatic breast cancerEUCTR2010-024266-21-ITISTITUTO EUROPEO DI ONCOLOGIA100
进行中（未招募）
不适用
A phase II study of metronomic oral chemotherapy with cyclophosphamide plus capecitabine combined with bevacizumab and erlotinib (BEXE), plus trastuzumab in HER2/neu positive tumors (BEXET), in advanced breast canceradvanced or metastatic breast cancerMedDRA version: 14.1Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2007-006025-27-ITISTITUTO EUROPEO DI ONCOLOGIA
Unknown
2 期
Metronomic Chemotherapy in Advanced Gastric CancerMetastatic Gastric CancerLocally Advanced Gastric CancerNCT02855788Huashan Hospital40
进行中（未招募）
不适用
A phase II study of metronomic oral chemoterapy with Cyclophosphamide plus Capecitabine combined with Trastuzumab in advanced breast cancer - NDPre-or post-menopausal women with histologically proven, locally advanced (inoperable) or metastatic breast cancer.EUCTR2009-017083-16-ITGOIM GRUPPO ONCOLOGICO MERIDIONALE